Stroke: Late Administration of Tenecteplase Limits Benefits
Late tenecteplase treatment (4.5-24 hours post-stroke) did not benefit patients with large-vessel occlusion stroke, but could help those with M1 occlusions, a new study showed.
Stay updated with breaking news from Perfusion Imaging. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late tenecteplase treatment (4.5-24 hours post-stroke) did not benefit patients with large-vessel occlusion stroke, but could help those with M1 occlusions, a new study showed.
Results from myocardial perfusion imaging of 2730 people with diabetes and no known coronary disease show impaired myocardial blood flow reserve predicts mortality regardless of ischemia symptoms.
Flurpiridaz has potential cost, convenience and ― especially for women and obese patients ― efficacy advantages over current PET perfusion methods.
1. The 90-day modified Ranking Scale score was comparable for patients in intravenous thrombolysis plus endovascular treatment versus endovascular treatment alone. 2. Intracranial hemorrhage was less frequent in the endovascular treatment alone group. Evidence Rating Level: 1 (Excellent) Study Rundown: Intravenous thrombolysis before endovascular treatment is the preferred therapy among patients with acute ischemic stroke; however,
1. The 90-day modified Ranking Scale score was comparable for patients in intravenous thrombolysis plus endovascular treatment versus endovascular treatment alone. 2. Intracranial hemorrhage was less frequent in the endovascular treatment alone group. Evidence Rating Level: 1 (Excellent) Study Rundown: Intravenous thrombolysis before endovascular treatment is the preferred therapy among patients with acute ischemic stroke;